[2-(.OMEGA.-Phenylalkyl)phenoxy]alkylamines. III. Synthesis and Selective Serotonin-2 Receptor Binding. (2).
作者:Naoki TANAKA、Riki GOTO、Rie ITO、Miho HAYAKAWA、Atsuhiro SUGIDACHI、Taketoshi OGAWA、Fumitoshi ASAI、Koichi FUJIMOTO
DOI:10.1248/cpb.48.1729
日期:——
A series of [2-(2-phenylethyl)phenoxy]ethylpyrrolidine derivatives were synthesized, and their affinity for serotonin-2 (5-HT2) and dopamine-2 (D2) receptors was examiend. Among them, compound 17, (2R, 4R)-4-hydroxy-2-[2-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]ehtyl]-1-methylpyrrolidine hydrochloride. showed high 5-HT2 receptor affinity in vitro. This compound was a more potent inhibitor of ex vivo 5-HT-induced platelet aggregation than compound 3, which was previously shown to be more potent than ketanserin (1) and sarpogrelate (2a). However, compound 17 produced gastric irritaiton in rats. Therefore, we carried out a further derivatization of 17, and compound 45 (R-102444), a lauryl ester prodrug of compound 17, was found to be a promising candidate as an antithrombotic agent. Oral administration of R-102444 produced a marked inhibition of 5-HT-induced ex vivo platelet aggregation, and R-102444 did not cause any gastric irritation. The antiaggregatory effects of R-102444 were more potent than those of sarpogrelate (2a) and its active metabolite, M-1 (2b). In addition, R-102444 exhibited more potent antithrombotic effects than sarpogrelate in a rat photochemically-induced thrombosis model.
这项研究合成了一系列[2-(2-苯乙基)苯氧基]乙基吡咯烷衍生物,并研究了它们对血清素-2(5-HT2)和多巴胺-2(D2)受体的亲和性。其中,化合物17[(2R,4R)-4-羟基-2-[2-[2-[2-(3-甲氧基苯基)乙基]苯氧基]乙基]-1-甲基吡咯烷盐酸盐]在体外显示出高5-HT2受体亲和力。这个化合物在体外抑制5-HT诱导的血小板聚集方面比化合物3更有效,而化合物3此前已被证明比酮色林(1)和沙格雷特(2a)更有效。
然而,化合物17在大鼠体内会引起胃部刺激。因此,研究人员对17进行了进一步衍生,发现化合物45(R-102444),即化合物17的月桂酯前药,是一个很有前途的抗血栓候选药物。口服R-102444能显著抑制5-HT诱导的体外血小板聚集,且不会引起任何胃部刺激。R-102444的抗聚集作用比沙格雷特(2a)及其活性代谢物M-1(2b)更强。此外,在大鼠光化学诱导血栓模型中,R-102444展现出比沙格雷特更强的抗血栓作用。